<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02109640</url>
  </required_header>
  <id_info>
    <org_study_id>2013-005327-16</org_study_id>
    <nct_id>NCT02109640</nct_id>
  </id_info>
  <brief_title>A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery</brief_title>
  <acronym>TACS</acronym>
  <official_title>A Randomized Blinded Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function After Colorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two key requirements for discharge from hospital after major abdominal surgery are adequate
      oral analgesia and resumption of oral nutrition. Up to 40% of patients suffer delayed
      discharge after abdominal surgery due to delayed return of gut function, manifesting as
      nausea, vomiting, constipation and abdominal distension. Opiates and their derivatives are
      the mainstay of postoperative analgesic regimens after abdominal surgery and are highly
      effective in achieving adequate pain control. However, opioids cause impaired gut function by
      reducing normal forward propulsion and increasing gut spasm. Opioid receptor blockers such as
      Alvimopan counteract these effects and can accelerate postoperative gut recovery but are
      expensive and cause cardiac complications; alternative painkillers such as non-steroidal
      anti-inflammatories are less effective than opioids and have been linked with increased risk
      of anastomotic leaks.

      Targinact is a combination of prolonged release opioid analgesic (oxycodone hydrochloride)
      and naloxone hydrochloride (an opioid receptor blocker). The formulation of the product
      confines the naloxone action to the gut to reduce the unwanted side-effects on gut function.
      Targinact has been shown in patients with chronic severe pain to provide comparable analgesia
      to other opioid analgesics whilst reducing the unwanted side-effect of constipation.

      The Investigators wish to test the hypothesis that Targinact will provide adequate analgesia
      after colonic resection with reduced postoperative gastrointestinal dysfunction. The surgical
      procedure chosen to test this hypothesis is laparoscopic segmental colectomy, a consistently
      reproducible intervention with a postoperative gut dysfunction rate of up to 40% (prospective
      data from the Edinburgh Colorectal Unit). The main outcome of the study will be return of
      normal gut function at the time of planned discharge (Day 3).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study hypothesis: Targinact is effective as oral analgesia after major colorectal surgery and
      is associated with less gut dysfunction than Oxycodone.

      Up to 40% of patients suffer delayed return of gut function after elective colorectal
      surgery, leading to prolonged hospital stay and higher inpatient costs. For the patient, this
      is characterised by a variety of symptoms including nausea and vomiting, delayed ability to
      regain normal oral intake, abdominal discomfort/distension and constipation. Although
      post-operative gut dysfunction tends to resolve spontaneously in 3-7 days, both symptoms and
      supportive treatment (nasogastric tube insertion, repeated venous cannulation for intravenous
      fluid administration etc) are unpleasant.

      Elective colorectal surgery is a common hospital intervention hence a reduction in the
      prevalence of post-operative gut dysfunction would be expected to benefit a large number of
      patients with attendant reduction in health service costs. The objective aligns well with the
      current national dissemination of Enhanced Recovery after Surgery programmes by the UK
      Department of Health and Scottish Government.

      Post-operative gut dysfunction is multifactorial. Opioid analgesics are contributory and all
      Enhanced Recovery after Surgery (ERAS) programmes emphasise strategies to minimise systemic
      opioid use (eg using regional or local anaesthetic techniques).

      Targinact has not been evaluated in the setting of short-term post operative analgesia in
      colorectal surgery but offers the potential to achieve effective analgesia with a lower
      incidence of gut dysfunction and therefore an important role within the ERAS program after
      colorectal surgery. Oxycodone is currently the oral opioid analgesic of choice in our unit
      and most patients are prescribed a combination of oxycodone and oxynorm as step-down
      analgesia following cessation of systemic or epidural analgesia, often in combination with
      fentanyl patches.

      Data will be collected from patient hospital records and questionnaires administered by the
      principal investigator and research study nurse.

      Multiple measures will be employed to record both presence of good function and absence of
      dysfunction.

        -  Time to first flatus

        -  Time to first bowel movement

        -  Time from surgery to cessation of iv fluids

        -  Total dose of rescue antiemetic (protocol ondansetron not included)

        -  Reinstitution of iv fluids (Y/N) Quantity of laxative used

        -  Measurement of oral nutritional intake:

      Preoperative intake will be recorded by means of a recall diary. Postoperative oral intake
      will be recorded by the participant using a food diary for 7 days from the date of surgery.
      Energy intake will then be estimated using CompEat Pro® forWindows® (Nutrition Systems,
      Banbury, UK). Time to attain and maintain 80% of normal solid food intake and the percentage
      Recommended Nutritional Intake (RNI) achieved on days 1-3 and days 5-7 after surgery will be
      used in comparisons between study groups.

        -  Validated nausea and vomiting score (Miles and Wengritzky)

        -  Presence of abdominal distension (Y/N)

        -  13C Stable Isotope Gastric Empyting Breath Test to measure gastric motility on the
           second postoperative morning. The technique has been previously used in the Edinburgh
           Department of Surgery and validated to be a reproducible and accurate measurement of
           upper GI motility.

      Additional data to be recorded:

        -  Patient demographics, co morbidity, regular medications

        -  Pre op bowel function questionnaire

        -  Postoperative nausea and vomiting prediction data (Apfel score)

        -  Day 3 achievement of discharge criteria (pain controlled by oral analgesia, tolerating
           adequate oral diet and fluids, independently mobile and willing to go home) Y/N

        -  30-day/Inpatient mortality

        -  Duration of hospital admission

        -  Complications (recorded by organ system and severity as assessed by Clavien/Dindo scale)

        -  Unscheduled readmissions to hospital within 30 days of discharge

        -  Patient-reported outcome questionnaire
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Postoperative Gut Dysfunction</measure>
    <time_frame>Day 3 post-op</time_frame>
    <description>The proportion of participants with gut dysfunction, defined as the presence of any of the following sufficient to delay discharge on the 3rd postoperative day: nausea, vomiting, intolerance of oral intake or constipation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Analgesia Consumption</measure>
    <time_frame>Total postoperative period of analgesic consumption, an average of 1 week</time_frame>
    <description>Total dose of systemic and oral Oxycodone or Targinact taken in hospital or at home until discontinued by the participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>Postoperative day 3</time_frame>
    <description>Overall Benefit of Analgesia Score (OBAS): Score range 0-28 with low score=high benefit. Summed from subscales of 0-4 for the following questions:
Please rate your current pain at rest on a scale between 0⁄4 minimal pain and 4⁄4 maximum imaginable pain
Please grade any distress and bother from vomiting in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from itching in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from sweating in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from freezing in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from dizziness in the past 24 h (0⁄4 not at all to 4⁄4 very much)
How satisfied are you with your pain treatment during the past 24 h (0⁄4 not at all to 4⁄4 very much) Lehmann N. British Journal of Anaesthesia 105 (4): 511-18 (2010)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Targinact</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Targinact 10-20mg bd following laparoscopic segmental colectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targinact</intervention_name>
    <description>Post-operative analgesia</description>
    <arm_group_label>Targinact</arm_group_label>
    <other_name>Oxycodone-Naloxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Postoperative analgesia</description>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic segmental colectomy</intervention_name>
    <arm_group_label>Targinact</arm_group_label>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective laparoscopic segmental colectomy at the Colorectal
             Surgery Unit, Western General Hospital, Edinburgh.

        Exclusion Criteria:

          -  Pregnancy Age &lt;18 years Patients lacking capacity to give informed consent. Severe
             liver dysfunction (Child's A or greater) Patients participating in another therapeutic
             clinical trial Contraindication to oxycodone, naloxone or Targinact Pre-existing
             dependence on opioid analgesia (current medications will be checked prior to
             discussing consent) Pre-existing use of opioid analgesia for chronic pain (current
             medications will be checked prior to discussing consent) Patients with rectal cancer
             Plan to form any stoma during procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh M Paterson, MD FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Lassen K, Soop M, Nygren J, Cox PB, Hendry PO, Spies C, von Meyenfeldt MF, Fearon KC, Revhaug A, Norderval S, Ljungqvist O, Lobo DN, Dejong CH; Enhanced Recovery After Surgery (ERAS) Group. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch Surg. 2009 Oct;144(10):961-9. doi: 10.1001/archsurg.2009.170. Review.</citation>
    <PMID>19841366</PMID>
  </reference>
  <reference>
    <citation>Hendry PO, Hausel J, Nygren J, Lassen K, Dejong CH, Ljungqvist O, Fearon KC; Enhanced Recovery After Surgery Study Group. Determinants of outcome after colorectal resection within an enhanced recovery programme. Br J Surg. 2009 Feb;96(2):197-205. doi: 10.1002/bjs.6445.</citation>
    <PMID>19160347</PMID>
  </reference>
  <reference>
    <citation>Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008 Dec;24(12):3503-12. doi: 10.1185/03007990802584454 .</citation>
    <PMID>19032132</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <results_first_submitted>November 23, 2016</results_first_submitted>
  <results_first_submitted_qc>February 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal</keyword>
  <keyword>Surgery</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Enhanced Recovery</keyword>
  <keyword>Targinact</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>62 patients consented to study participation but 12 were not assigned to the study. This was because consent was obtained a few weeks before the date of surgery and in that interval 12 patients became ineligible (change of planned operation, presentation as emergency, development of ineligibility criteria, withdrawn from anaesthetic protocol).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Targinact</title>
          <description>Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
Targinact: Post-operative analgesia
Laparoscopic segmental colectomy</description>
        </group>
        <group group_id="P2">
          <title>Oxycodone</title>
          <description>Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
Oxycodone: Postoperative analgesia
Laparoscopic segmental colectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Targinact</title>
          <description>Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
Targinact: Post-operative analgesia
Laparoscopic segmental colectomy</description>
        </group>
        <group group_id="B2">
          <title>Oxycodone</title>
          <description>Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
Oxycodone: Postoperative analgesia
Laparoscopic segmental colectomy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Postoperative Gut Dysfunction</title>
        <description>The proportion of participants with gut dysfunction, defined as the presence of any of the following sufficient to delay discharge on the 3rd postoperative day: nausea, vomiting, intolerance of oral intake or constipation.</description>
        <time_frame>Day 3 post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Targinact</title>
            <description>Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
Targinact: Post-operative analgesia
Laparoscopic segmental colectomy</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
Oxycodone: Postoperative analgesia
Laparoscopic segmental colectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Postoperative Gut Dysfunction</title>
          <description>The proportion of participants with gut dysfunction, defined as the presence of any of the following sufficient to delay discharge on the 3rd postoperative day: nausea, vomiting, intolerance of oral intake or constipation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <p_value_desc>Absolute % difference 17.1 (95% CI -10.0,40.7)</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Absolute percentage difference</param_type>
            <param_value>17.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>40.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Opioid Analgesia Consumption</title>
        <description>Total dose of systemic and oral Oxycodone or Targinact taken in hospital or at home until discontinued by the participant</description>
        <time_frame>Total postoperative period of analgesic consumption, an average of 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Targinact</title>
            <description>Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
Targinact: Post-operative analgesia
Laparoscopic segmental colectomy</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
Oxycodone: Postoperative analgesia
Laparoscopic segmental colectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Analgesia Consumption</title>
          <description>Total dose of systemic and oral Oxycodone or Targinact taken in hospital or at home until discontinued by the participant</description>
          <units>milligram morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="36"/>
                    <measurement group_id="O2" value="94" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.222</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores</title>
        <description>Overall Benefit of Analgesia Score (OBAS): Score range 0-28 with low score=high benefit. Summed from subscales of 0-4 for the following questions:
Please rate your current pain at rest on a scale between 0⁄4 minimal pain and 4⁄4 maximum imaginable pain
Please grade any distress and bother from vomiting in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from itching in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from sweating in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from freezing in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from dizziness in the past 24 h (0⁄4 not at all to 4⁄4 very much)
How satisfied are you with your pain treatment during the past 24 h (0⁄4 not at all to 4⁄4 very much) Lehmann N. British Journal of Anaesthesia 105 (4): 511–18 (2010)</description>
        <time_frame>Postoperative day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Targinact</title>
            <description>Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
Targinact: Post-operative analgesia
Laparoscopic segmental colectomy</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
Oxycodone: Postoperative analgesia
Laparoscopic segmental colectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores</title>
          <description>Overall Benefit of Analgesia Score (OBAS): Score range 0-28 with low score=high benefit. Summed from subscales of 0-4 for the following questions:
Please rate your current pain at rest on a scale between 0⁄4 minimal pain and 4⁄4 maximum imaginable pain
Please grade any distress and bother from vomiting in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from itching in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from sweating in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from freezing in the past 24 h (0⁄4 not at all to 4⁄4 very much)
Please grade any distress and bother from dizziness in the past 24 h (0⁄4 not at all to 4⁄4 very much)
How satisfied are you with your pain treatment during the past 24 h (0⁄4 not at all to 4⁄4 very much) Lehmann N. British Journal of Anaesthesia 105 (4): 511–18 (2010)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.676</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days postoperative</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Targinact</title>
          <description>Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
Targinact: Post-operative analgesia
Laparoscopic segmental colectomy</description>
        </group>
        <group group_id="E2">
          <title>Oxycodone</title>
          <description>Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
Oxycodone: Postoperative analgesia
Laparoscopic segmental colectomy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Intraabdominal fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Self-limiting postop</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Wound healing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute urinary retention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxaemia postop</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hugh M Paterson</name_or_title>
      <organization>University of Edinburgh</organization>
      <phone>44 131 537 1000</phone>
      <email>hugh.paterson@ed.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

